Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Creative Medical Technology HoldingsCELZ +5.53%28 3-Year EBITDA Growth Rate is 35.20% as of Jun. 2026, which is 57% below its 10-year median of 81.30. GuruFocus rates CELZ with a GF Score™ of 28/100 and a GF Value™ of $0.49 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Creative Medical Technology Holdings ranks better than 73.82% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Creative Medical Technology Holdings was 85.90% per year. The lowest was 35.20% per year. And the median was 81.30% per year.
Creative Medical Technology Holdings (NAS:CELZ) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Creative Medical Technology Holdings 3-Year EBITDA Growth Rate Related Terms
CELZ vs BOLT, ENSC, NCNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Creative Medical Technology Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Creative Medical Technology Holdings's 3-Year EBITDA Growth Rate falls into.
Creative Medical Technology Holdings 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.20% mean?
Creative Medical Technology Holdings (CELZ) has a 3-Year EBITDA Growth Rate of 35.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Creative Medical Technology Holdings and its competitors. This is 57% below median its historical median of 81.30. Over the past decade, Creative Medical Technology Holdings' 3-Year EBITDA Growth Rate has ranged from 35.20 to 85.90. According to the industry distribution chart, Creative Medical Technology Holdings ranks #295 out of 1127 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Creative Medical Technology Holdings' 3-Year EBITDA Growth Rate too high?
Creative Medical Technology Holdings' current 3-Year EBITDA Growth Rate of 35.20% is 57% below median its 10-year median of 81.30. Over the past 10 years, this metric has ranged from a low of 35.20 to a high of 85.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Creative Medical Technology Holdings' value of 35.20% is 141.1% above this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #295 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Creative Medical Technology Holdings has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' 3-Year EBITDA Growth Rate compare to BOLT and ENSC?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #295 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Creative Medical Technology Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Creative Medical Technology Holdings' value of 35.20% is 141.1% above this benchmark. Historically, Creative Medical Technology Holdings' own 3-Year EBITDA Growth Rate has ranged from 35.20 to 85.90 over the past decade. While the company's 10-year median is 81.30 vs. the industry median of 14.60, Creative Medical Technology Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current 3-Year EBITDA Growth Rate of 35.20% is 141.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current 3-Year EBITDA Growth Rate is 35.20%, which is 57% below median its own 10-year median of 81.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.49, compared to a current price of $1.11 — trading 126.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 35.20%, which is 57% below median its 10-year median of 81.30 and 141.1% above the Biotechnology industry median of 14.60. Creative Medical Technology Holdings' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current 3-Year EBITDA Growth Rate is 35.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $1.11 is trading 126.5% above its estimated GF Value™ of $0.49.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
3-Year EBITDA Growth Rate: 35.20% (57% below median its 10-year median of 81.30)
GF Value™: $0.49 vs. price of $1.11 (126.5% above fair value)
Industry Position: 141.1% above the Biotechnology median (#295 of 1127)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
28GF Score
Get the complete analysis for CELZ
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
